PTGIR
Prostacyclin receptor
As of the edition of 20 October 2026, PTGIR (prostacyclin receptor, UniProt P43119) has 8 drugs tested at it and 12 companies on the list, 2 on route A and 6 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P43119
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 2
- Disease areas
- Lungs and airways; Heart and blood vessels; Skin and connective tissue; Infections; Inherited and neonatal; Pregnancy and women's health; Urinary and reproductive; Cancer
- Registered trials of its drugs
- 245
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 2 |
| Stopped | 2 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Treprostinil | Marketed | Phase 4 | Ends 2028 |
| Iloprost | Marketed | Phase 4 | none listed |
| Selexipag | Marketed | Phase 4 | Ends 2030 |
| Epoprostenol | Marketed | Phase 4 | none listed |
| Beraprost | Stopped | Phase 4 | none listed |
| Ralinepag | Active | Phase 3 | none listed |
| Esuberaprost | Stopped | Phase 3 | none listed |
| LIQ861 | Active | No phase stated | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 6 |
| Engaged | 3 |
| Undetermined | 1 |
| Total on the list | 12 |
| Company | Route |
|---|---|
| GSK | Route B |
| United Therapeutics | Route B |
| Astellas | Route A |
The other 9 companies at PTGIR
In the product12 companies in all; 9 are not named here, and no score is.
See the 12 companies at PTGIR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.